Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Geron Corporation (GERN : NSDQ)

• Company Description    Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. Number of Employees: 229

• Price / Volume Information    Yesterday's Closing Price: $1.27 Daily Weekly Monthly 20 Day Moving Average: 6,178,472 shares Shares Outstanding: 638.02 (millions) Market Capitalization: $810.28 (millions) Beta: 0.63 52 Week High: $4.83 52 Week Low: $1.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.41% -13.95% 12 Week -18.06% -25.57% Year To Date -64.12% -66.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 919 EAST HILLSDALE BOULEVARD SUITE 250 - FOSTER CITY,CA 94404 USA ph: 650-473-7700 fax: 650-473-7750 investor@geron.com http://www.geron.com

• General Corporate Information    Officers JOHN A. SCARLETT - President; Chief Executive Officer and Chairman MICHELLE ROBERTSON - Executive Vice President; Finance; Chief Financi GAURAV AGGARWAL - Director DAWN C. BIR - Director V. BRYAN LAWLIS - Director Peer Information Geron Corporation (CORR.) Geron Corporation (RSPI) Geron Corporation (CGXP) Geron Corporation (BGEN) Geron Corporation (GTBP) Geron Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 374163103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 638.02 Most Recent Split Date: (:1) Beta: 0.63 Market Capitalization: $810.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.12 Price/Cash Flow: - Price / Sales: 4.93 EPS Growth vs. Year Ago Period: 80.00% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: 5,459.64% vs. Previous Quarter: 23.82% ROE 06/30/25 - -31.37 03/31/25 - -47.86 12/31/24 - -56.48 ROA 06/30/25 - -16.01 03/31/25 - -26.78 12/31/24 - -35.10 Current Ratio 06/30/25 - 7.87 03/31/25 - 7.87 12/31/24 - 5.56 Quick Ratio 06/30/25 - 6.79 03/31/25 - 6.97 12/31/24 - 5.12 Operating Margin 06/30/25 - -52.48 03/31/25 - -118.07 12/31/24 - -224.51 Net Margin 06/30/25 - -53.52 03/31/25 - -119.54 12/31/24 - -226.73 Pre-Tax Margin 06/30/25 - -53.52 03/31/25 - -119.54 12/31/24 - -226.74 Book Value 06/30/25 - 0.41 03/31/25 - 0.42 12/31/24 - 0.46 Inventory Turnover 06/30/25 - 0.08 03/31/25 - 0.08 12/31/24 - 0.08 Debt-to-Equity 06/30/25 - 0.46 03/31/25 - 0.44 12/31/24 - 0.42 Debt-to-Capital 06/30/25 - 31.44 03/31/25 - 30.68 12/31/24 - 29.71

Powered by Zacks Investment Research ©